© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:732-742 Percutaneous, transendocardial injection of bone marrow-derived mononuclear.

Slides:



Advertisements
Similar presentations
Early Impaired Myocardial Perfusion is Associated with Larger SPECT Infarct Size Patients with a closed myocardium (TMPG 0/1) and patients without complete.
Advertisements

Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic.
prognosis of patients with Acute Myocardial Infarction remains dismal.
Trial profile Fox K et al. Lancet 2008;372:
MEDICAL TERMINOLOGY
Stem cells and gene therapy to repair the damaged heart: will it work and is it right? John Martin Professor of Cardiovascular Medicine University College.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8:87-93 Impact of age on clinical outcomes after everolimus-eluting and paclitaxel-eluting.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Comparison of intravascular ultrasound versus angiography-guided drug-eluting.
© 2012 EuroIntervention. All rights reserved. EuroIntervention 2009;5: A comparison of patient characteristics and 30-day mortality outcomes after.
American Heart Association. Available at Accessed February
Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction by Mortimer Korf-Klingebiel,
Percutaneous Autologous Bone-Marrow Grafting for Nonunions by Ph. Hernigou, A. Poignard, F. Beaujean, and H. Rouard J Bone Joint Surg Am Volume 87(7):
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Control of Sympathetic Drive With Continuous.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effect of Clopidogrel Pretreatment Before Percutaneous.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Diagnoses and Timing of 30-Day Readmissions After.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Incidence, Temporal Trends, and Prognostic Impact.
Date of download: 6/3/2016 From: Radial Versus Femoral Access in Invasively Managed Patients With Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Micro-RNA-34a Contributes to the Impaired Function.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Prognostic Importance of Physical Examination for.
Date of download: 7/7/2016 Copyright © The American College of Cardiology. All rights reserved. From: Stem Cell Mobilization by Granulocyte Colony-Stimulating.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of Controlled-Release Metoprolol on Total.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
A Statewide Collaborative Initiative to Improve the Quality of Care for Patients With Acute Myocardial Infarction and Heart Failure Circulation. 2009;119:
Date of download: 9/20/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Aging on Human Mesenchymal Stem Cell Therapy.
Discontinuation of medication after nonfatal event: MI
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
Exercise capacity and quality of life after intracoronary injection of autologous mononuclear bone marrow cells in acute myocardial infarction: Results.
Copyright © 2007 American Medical Association. All rights reserved.
Volume 130, Issue 5, Pages (November 2012)
PP-183 [AJC » Percutaneous coronary interventions in acute coronary syndromes] Succesful Treatment and Management of LMCA Acute Total Occlusion in a Patient.
Copyright © 2009 American Medical Association. All rights reserved.
Figure 1 Patient flow chart.
Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.
Figure 3 One-year adverse events (death, post-discharge myocardial infarction, revascularization) after PCI according to patients who (A) would not have.
Copyright © 2005 American Medical Association. All rights reserved.
Figure 1 Incidence and total numbers of SCD in patients with depressed LV systolic function and in patients with preserved LV function. The incidence of.
Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.
Circ Cardiovasc Interv
Circ Cardiovasc Qual Outcomes
TECAM Trial design: STEMI patients who underwent successful reperfusion therapy were randomized on day 1 to intracoronary bone marrow autologous mononuclear.
Cardiac Biomarkers: Key Takeaways for Use in Heart Failure and Acute Coronary Syndrome.
POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.
MOBILE Trial design: Patients with critical limb ischemia were randomized to intramuscular injection of bone marrow-derived stem cells (n = 119) vs. placebo.
Nat. Rev. Cardiol. doi: /nrcardio
NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.
Why surgery won the SYNTAX trial and why it matters
Coronary artery bypass grafting using the gastroepiploic artery in 1,000 patients  Hitoshi Hirose, MD, Atushi Amano, MD, Shuichirou Takanashi, MD, Akihito.
The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.
Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.
(A) A patient with anterior acute myocardial infarction with grade II ischaemia. (A) A patient with anterior acute myocardial infarction with grade II.
Nat. Rev. Cardiol. doi: /nrcardio
Flow Diagram of the Trial Selection Process
(A) Meta-analysis of repeat revascularisation in randomised trials.
Behnam N. Tehrani et al. JACC 2019;73:
Eduardo Marbán, MD, PhD  Mayo Clinic Proceedings 
Name that bone....
Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)
Characteristics of included studies
Total Arterial Off-Pump Coronary Surgery: Time to Change Our Habits?
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
A patient with inferior acute myocardial infarction with grade II ischaemia. A patient with inferior acute myocardial infarction with grade II ischaemia.
Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.
Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.
Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Traditional cardiovascular risk factors can cause cardiac disease in patients with IIM. Systemic and local inflammation may either have a direct effect.
Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.
Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.
Presentation transcript:

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

© 2012 EuroIntervention. All rights reserved. EuroIntervention 2012;8: Percutaneous, transendocardial injection of bone marrow-derived mononuclear cells in heart failure patients following acute ST-elevation myocardial infarction: ALSTER-Stem Cell trial

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.